波氏假阿利什霉复合种对4种抗真菌药物的敏感性研究

中国真菌学杂志　 2015, Vol. 10 　Issue (2): 96-99.

波氏假阿利什霉复合种对4种抗真菌药物的敏感性研究

王红, 万喆, 余进

北京大学第一医院皮肤科北京大学真菌和真菌病研究中心皮肤病分子诊断北京市重点实验室, 北京 100034

收稿日期:2014-10-21 出版日期:2015-04-28 发布日期:2015-04-28
通讯作者: 余进,E-mail:yujin@medmail.com.cn E-mail:yujin@medmail.com.cn
作者简介:王红,女(汉族),硕士研究生在读.E-mail:wanghong5018@126.com

In vitro susceptibility test of clinical isolates of Pseudallescheria boydii complex to four anti-fungus agents

WANG Hong, WAN Zhe, YU Jin

Department of Dermatology and Venereology, Peking University First Hospital, Research Center for Medical Mycology, Peking University, Beijing 100034, China

Received:2014-10-21 Online:2015-04-28 Published:2015-04-28

摘要/Abstract

摘要：

目的对23株分子鉴定为赛多孢霉复合种的菌株检测其对伏立康唑、泊沙康唑、伊曲康唑和两性霉素B的敏感性。方法参照美国临床实验室标准化研究所制定的M38-A2方案,检测临床来源的9株波氏假阿利什霉 (Pseudallescheria boydii)、6株P.ellipsoidea、1株P.angusta、1株P.fusoidea和6株尖端赛多孢 (Scedosporium apiospermum)对伏立康唑、泊沙康唑、伊曲康唑和两性霉素B的MIC值。结果伏立康唑对所有受试菌株的MIC值为0.25~1 μg/mL,泊沙康唑为2~4 μg/mL。伊曲康唑对P.ellipsoidea、尖端赛多孢的MIC值为2~>16 μg/mL,对波氏假阿利什霉、P.angusta、P.fusoidea的MIC值为2~4 μg/mL。两性霉素B对5种菌的MIC值均为为4~>16 μg/mL。结论伏立康唑、泊沙康唑、伊曲康唑和两性霉素B对波氏假阿利什复合种中不同种的敏感性未见明显差异。该复合种对伏立康唑最敏感,泊沙康唑其次,伊曲康唑变化较大,两性霉素B的效果最差。

关键词: 波氏假阿利什霉复合种, 伏立康唑, 泊沙康唑, 伊曲康唑, 两性霉素B

Abstract:

Objective To determine the in vitro susceptibility of Pseudallescheria boydii complex to voriconazole(VRC),posaconazole(POS),itraconazole(ITC)and amphotericin B(AMB).Methods The MICs of VRC,POS,ITC and AMB were determined according to M38-A2 methods in nine isolates of P.boydii,six isolates of P.ellipsoidea,one isolate of P.angusta,one isolate of P.fusoidea and six isolates of S.apiospermum.Results The MIC range of VRC and POS were 0.25-1 μg/mL and 2-4 μg/mL.ITC had higher MIC range which was 2->16 μg/mL against P.ellipsoidea and S.apiospermum than P.boydii,P.angusta,and P.fusoidea(2-4 μg/mL).The MIC range of AMB against all the species was 4->16 μg/mL.Conclusion VRC,POS,ITC and AMB have the similar susceptibility patterns against various types of Pseudallescheria boydii complex.Since ITC was more sensitive to P.boydii,P.angusta and P.fusoidea than P.ellipsoidea and S.apiospermum in our study,VRC is the most sensitive drug against all the types and than POS and AMB is the worst one among the four drugs.

Key words: Pseudallescheria boydii complex, voriconazole, posaconazole, itraconazole, amphotericin B

中图分类号:

R379.9

王红, 万喆, 余进. 波氏假阿利什霉复合种对4种抗真菌药物的敏感性研究[J]. 中国真菌学杂志, 2015, 10(2): 96-99.

WANG Hong, WAN Zhe, YU Jin. In vitro susceptibility test of clinical isolates of Pseudallescheria boydii complex to four anti-fungus agents[J]. Chinese Journal of Mycology, 2015, 10(2): 96-99.

参考文献

[1] Malloch D,Salk in IF.A new species of Scedosporium associated with osteom yelitis in humans
[J].Mycotaxon,1984,21:247-255.

[2] Patrick RM,Ellen JB,Michael AP,et al.Manual of clinical microbiology
[M].8^th ed Washington ASM press,2003:1848-1856.

[3] Pedro I,Emilio PT,Luis P,et al.Disseminated infection and colonization by Scedosporium prolificans:a review of 18 cases 1990-1999
[J].Clin Infect Dis,2001,32(11):158-165.

[4] Gilgado F,Cano J,Gené J,et al.Molecular phylogeny of the Pseudallescheria boydii species complex:proposal of two new species
[J].J Clin Microbiol,2005,43(10):4930-4942.

[5] 王思卜,张杰,余进,等.用ITS和TUB序列差异鉴定临床相关波氏假阿利什霉/尖端赛多孢
[J].中国检验医学杂志,2011,34(12):1084-1087.

[6] Kaltseis J,Rainer J,De Hoog GS.Ecology of Pseudallescheria and Scedosporium species in human-dominated and natural environments and their distribution in clinical samples
[J].Med Mycol,2009,47(4):398-405.

[7] Zouhair R,Rougeron A,Razafimandimby B,Kobi A,et al.Distribution of the different species of the Pseudallescheria boydii/Scedosporium apiospermum complex in French patients with cystic fibrosis
[J].Med Mycol,2013,51(6):603-613.

[8] Lackner M,Rezusta A,Villuendas MC,et al.Infection and colonisation due to Scedosporium in Northern Spain.An in vitro antifungal susceptibility and molecular epidemiology study of 60 isolates
[J].Mycoses,2011,54(3):12-21.

[9] Cuenca-Estrella M,Ruiz-Diez B,Martinez-Suarez JV,et al.Comparative in-vitro activity of voriconazole(UK-109,496)and six other antifungal agents against clinical isolates of Scedosporium prolificans and Scedosporium apiospermum
[J].J Antimicrob Chemother,1999,43(1):149-151.

[10] Carrillo AJ,Guarro J.In vitro activities of four novel triazoles against Scedosporium spp
[J].Antimicrob Agents Chemother,2001,45(7):2151-2153.

[11] Cuenca-Estrella M,Gomez-Lopez A,Mellado E,et al.In vitro activity of ravuconazole against 923 clinical isolates of nondermatophyte filamentous fungi
[J].Antimicrob Agents Chemother,2005,49(12):5136-5138.

[12] Lackner M,de Hoog GS,Verweij PE,et al.Species-specific antifungal susceptibility patterns of Scedosporium and Pseudallescheria species
[J].Antimicrob Agents Chemother,2012,56(5):2635-2642.

[13] Lackner M,Hagen F,Meis JF,et al.Susceptibility and diversity in the therapy-refractory genus Scedosporium
[J].Antimicrob Agents Chemother,2014,58(10):5877-5885.

[14] 王澎,徐英春,窦洪涛,等.尖端赛多孢和多育赛多孢所致深部真菌感染2例并文献复习
[J].中国真菌学杂志,2007,2(4):210-213.

[15] 帕丽达·阿布利孜,Takashi Yaguchi,罗德梅,等.多育赛多孢菌性鼻窦炎1例-致病菌的鉴定和体外抗真菌药物敏感性研究
[J].中国真菌学杂志,2010,5(1):1-4.

[16] 万喆,余进,陈少杰,等.卡泊芬净联合伏立康唑、伊曲康唑或两性霉素B对尖端赛多孢子菌体外抑菌活性
[J].中国临床药理学杂志,2010,26(7):499-501.

[17] Cuenca-Estrella M,Alastruey-Izquierdo A,Alcazar-Fuoli L,et al.In vitro activities of 35 double combinations of antifungal agents against Scedosporium apiospermum and Scedosporium prolificans
[J].Antimicrob Agents Chemother,2008,52(3):1136-1139.